Zydus Lifesciences announced its Q2 FY26 results, showcasing a boost in total income to ₹62.32 billion. Profit after tax stood at ₹12.59 billion. The company’s performance was bolstered by substantial dividend income from subsidiaries and joint ventures, amounting to ₹4.19 billion. The Board has also approved the unaudited financial results for the quarter and half-year ended September 30, 2025.
Financial Performance
Zydus Lifesciences reported a total income of ₹62.32 billion for the quarter ended September 30, 2025, compared to ₹67.29 billion in the previous quarter and ₹53.05 billion in the corresponding quarter last year. The profit after tax was reported as ₹12.59 billion. The earnings per share for continuing operations stood at ₹12.51.
Segmental Overview
The company’s revenue from Pharmaceuticals segment stood at ₹54.74 billion, while the Consumer Products segment contributed ₹6.49 billion to the total revenue. The Pharmaceuticals segment reported a profit of ₹17.39 billion before tax, and the Consumer Products segment reported ₹0.16 billion profit before tax.
Key Financial Highlights
Key highlights from the report include:
- Total expenses: ₹45.11 billion
- Tax expenses: ₹4.54 billion
- Other Comprehensive Income: ₹(2.74) billion
Dividend income from subsidiaries and joint ventures accounted for ₹4.19 billion for the quarter and half year ended September 30, 2025.
Acquisition and Expansion
Zydus Lifesciences has been actively expanding its business through acquisitions. A subsidiary, Alidac UK Limited, completed the acquisition of Comfort Click Limited (CCL) on August 29, 2025. Furthermore, the company successfully completed the acquisition of Amplitude Surgical SA, France, on July 29, 2025.
Trading Window
The trading window, under SEBI regulations, will remain closed for trading until November 8, 2025, and will reopen on November 10, 2025.
Source: BSE
